Format

Send to

Choose Destination
Sci Rep. 2016 Nov 10;6:36234. doi: 10.1038/srep36234.

Cytokine cascade and networks among MSM HIV seroconverters: implications for early immunotherapy.

Author information

1
Center for Infectious Diseases, Beijing You'an Hospital, Capital Medical University, Beijing 100069, China.
2
Infectious Diseases Department, Peking Union Medical College Hospital, Beijing, 100730, China.
3
The Aaron Diamond AIDS Research Center, New York, NY 10016, United States.
4
School of Biomedical Engineering, Capital Medical University, Beijing 100069, China.

Abstract

The timing, intensity and duration of the cytokine cascade and reorganized interrelations in cytokine networks are not fully understood during acute HIV-1 infection (AHI). Using sequential plasma samples collected over three years post-infection in a cohort of MSM HIV-1 seroconvertors, we determined the early kinetics of cytokine levels during FiebigI-IV stages using Luminex-based multiplex assays. Cytokines were quantified and relationships between cytokines were assessed by Spearman correlation. Compared with HIV-negative MSM, HIV-infected individuals had significantly increased multiple plasma cytokines, including GM-CSF, IFN-α2, IL-12p70, IP-10 and VEGF, during both acute and chronic stages of infection. Furthermore, rapid disease progressors (RDPs) had earlier and more robust cytokine storms, compared with slow disease progressors (SDPs) (49.6 days vs. 74.9 days, respectively; 6.7-fold vs. 3.7-fold change of cytokines, respectively), suggesting the faster and stronger cytokine storm during AHI could promote disease progression. On the other hand, HIV-1 infection induced more interlocked cytokines network, establishing new strong correlations and imposing a higher rigidity. There were, respectively, 146 (44.9%) statistically significant correlations of cytokines in RDPs and 241 (74.2%) in SDPs (p < 0.001). This study suggests that immunomodulatory interventions aimed at controlling cytokine storm in AHI may be beneficial to slow eventual disease progression.

PMID:
27830756
PMCID:
PMC5103227
DOI:
10.1038/srep36234
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center